Table 5

Model-based age-adjusted 5-year relative survival in 2002 and 2006 by histology and stage for endometrial cancer patients diagnosed in Germany, 1997-2006

Histology

Stagea

2002 (1)

2006 (2)

Change of RS

(2)-(1)

P-valueb


Count

RS (SE)

Count

RS (SE)


Adenocarcinoma

3,511

82.6 (0.7)

3,495

84.5 (0.6)

1.9

0.066

Adenocarcinoma, NOS

1,526

84.7 (1.0)

700

84.3 (1.1)

-0.3

0.848

Papillary/clear cellc

322

67.0 (2.7)

186

68.9 (2.6)

1.9

0.643

Mucinous/squamous/

adenosquamous

228

80.5 (3.2)

157

85.2 (2.5)

4.7

0.265

Endometrioid

1,435

85.7 (0.9)

2,452

85.8 (0.9)

0.1

0.961

Sarcoma

199

48.6 (2.6)

223

39.7 (2.6)

-8.9

0.048

Others (mixture) d

93

55.8 (4.1)

91

54.1 (4.1)

-1.7

0.789

All

Localized

1,409

90.5 (1.0)

1,497

91.8 (0.9)

1.3

0.362

Regional

91

47.0 (4.2)

137

53.3 (4.0)

6.3

0.368

Distant

116

19.4 (2.8)

146

21.4 (2.9)

2.0

0.641

Overall

1,616

82.8 (0.9)

1,780

83.4 (0.9)

0.5

0.721


Abbreviations: NOS = not otherwise specified; RS = point estimate of relative survival (%); SE = standard error (percent units);

a restricted to cases with complete stage information;

b the differences between RS (percent units) were tested using model-based period analysis;

c including other adenocarcinoma;

d including carcinoma NOS.

Chen et al. BMC Cancer 2012 12:128   doi:10.1186/1471-2407-12-128

Open Data